Therapeutic advances: Leukotriene antagonists for the treatment of asthma

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 1, 1999, Pages 17-22

  Misson, J ^a   Clark, W ^a   Kendall, M J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; ERYTHROMYCIN; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PHENYTOIN; STEROID; TERFENADINE; THEOPHYLLINE; WARFARIN; ZAFIRLUKAST;

ADOLESCENT; ADULT; ASTHMA; BLOOD VESSEL PERMEABILITY; BRONCHOSPASM; CHILD; CHURG STRAUSS SYNDROME; DRUG EFFICACY; EXERCISE INDUCED ASTHMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MUCUS SECRETION; ORAL DRUG ADMINISTRATION; PEDIATRICS; REVIEW;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHOCONSTRICTION; CAPILLARY PERMEABILITY; CHILD; HUMANS; LEUKOTRIENE ANTAGONISTS; MUCUS; TREATMENT OUTCOME;

EID: 0032929887     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00191.x     Document Type: Review

References (17)

1. 1. Anderson HR. (1989) Is the prevalence of asthma changing? Archive Diseases of Childhood, 64, 172-175.
2. 2. Burney PGJ, Chinn S, Rona RJ. (1990) Has the prevalence of asthma increased in children? Evidence from the national study of health and growth 1973-86. British Medical Journal, 300, 1306-1310.
3. 3. British Thoracic Society. (1997) The British Guidelines on Asthma Management. Thorax, 52(Suppl.1), 51-528.
4. 4. Adkins JC, McTavish D. (1997) Salmeterol. A review of its pharmacological properties and efficacy in the management of children with asthma. Drugs, 54(2), 331-354.
5. 5. Spector SL. (1997) Leukotriene activity modulation in asthma. Drugs, 54(3), 369-384.
6. 6. Sampson A, Holgate S. (1998) Leukotriene modifiers in the treatment of asthma. British Medical Journal, 316, 1257-1258.
7. 7. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. (1980) Leukotrienes are potent constrictors of human bronchi. Nature, 288, 484-486.
8. 8. Smith LJ, Greenberger PA, Patterson R, Krell RD, Bernstein PR. (1985) The effect of inhaled leukotriene D4 in humans. American Reviews in Respiratory Disease, 131, 368-372.
9. 9. Adelroth E, Morris M, Hargreave FE, O'Byrne PM. (1986) Airway responsiveness to leukotrienes C4 and methacoline in patients with asthma and normal controls. New England Journal of Medicine, 315, 480-484.
10. 10. Reiss TF, Chervinsky P, Dockhorn RJ, et al. (1998) Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma, A multicentre, randomised, double-blind trial. Archives of Internal Medicine, 158, 1213-1220.
11. 11. Knorr B, Matz J, Bernstein JA, et al. (1998) Montelukast for chronic asthma in 6-14-year-old children. A randomised, double-blind trial. Journal of the American Medical Association, 279, 1181-1186.
12. 12. Leff JA, Busse WW, Pearlman D, et al. (1998) Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. New England Journal of Medicine, 339, 147-152.
13. 13. Leff JA, Israel E, Noonan MJ, Finn AF, Godard P, et al. (1997) Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability. American Journal of Respiratory Critical Care Medicine, 155 (4, Part 2), A976.
14. 14. Holgate ST, Anderson KD, Rodgers EM. (1995) Comparison of Accolate® (zafirlukast) with sodium cromoglygate in mild to moderate asthmatic patients. (abstract) Allergy, 50(Suppl.26), 319-320.
15. 15. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, et al. (1997) Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clinical Therapeutics, 19(4), 675-690.
16. 16. Laitinen LA, Zetterstrom O, Holgate ST, Binks SM, Whitney JG. (1995) Effects of Accolate® (zafirlukast; 20mg bd) in permitting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroid optimised between 800 and 2000 μg per day. (abstract) Allergy, 50(Suppl.26), 320.
17. 2-agonists. European Respiratory Journal, 10(Suppl.25), 419s.